Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 3/20 | 0.55 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.50 |
| ▸ | P4HB | P07237 | 11/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31546284 | 0.87 | FBP1 (0.54) | FBP1PDCD1CD274GRIN2DGRIN3B | |
| SCHEMBL28302510 | 0.82 | ALDH1A1 (0.55) | FBP1PDCD1CD274GRIN2DGRIN3B | |
| SCHEMBL6981746 | 0.82 | AKR1C3 (0.59) | FBP1PDCD1CD274GRIN2DGRIN3B | |
| Balazipone SCHEMBL636109 | 0.82 | PDCD1 (0.55) | FBP1PDCD1CD274GRIN2DGRIN3B | |
| SCHEMBL5970912 | 0.82 | PDCD1 (0.51) | FBP1PDCD1CD274GRIN2DGRIN3B | |
| SCHEMBL3115027 | 0.82 | AKR1C3 (0.59) | FBP1PDCD1CD274GRIN2DGRIN3B | |
| SCHEMBL28372992 | 0.82 | AKR1C3 (0.59) | FBP1PDCD1CD274GRIN2DGRIN3B | |
| SCHEMBL5970541 | 0.82 | ALDH1A1 (0.55) | FBP1PDCD1CD274GRIN2DGRIN3B | |
| SCHEMBL1554030 | 0.81 | SLC9A1 (0.48) | FBP1 | |
| SCHEMBL6492531 | 0.81 | FBP1 (0.55) | FBP1PDCD1CD274GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| EP-0458207-B1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-03-26 | — | — | EP | disclosed |
| US-5312829-A | Testosterone 5alpha-reductase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-17 | — | — | US | disclosed |
| US-5212320-A | Enzyme inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-05-18 | — | — | US | disclosed |
| EP-0458207-A2 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | ERG28, CYP51A1, XPO1 | FBP1 863/4885PDCD1 2133/4885CD274 1906/4885 |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | XPO1, THPO, G6PD | FBP1 842/4885PDCD1 3995/4885CD274 4354/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | FBP1 746/4885PDCD1 2014/4885CD274 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.